LB PHARMACEUTICALS INC 8-K

What Happened

• LB Pharmaceuticals Inc. announced that on March 13, 2026 director Zachary Prensky informed the Board he will retire and will not stand for reelection at the Company’s 2026 Annual Meeting of stockholders. His current term will end at the conclusion of that meeting, and he will remain on the Board and the Nominating and Corporate Governance Committee until then.
• The company and Mr. Prensky entered into Amendment No. 1 to a Transition, Separation, and Consulting Agreement (effective June 3, 2026), which continues his provision of consulting services and related benefits. The amendment also allows Mr. Prensky’s outstanding unvested stock options to remain eligible to vest for the duration of the amended agreement. The decision to resign was not due to any disagreement with the Company.

Key Details

• Notification date: March 13, 2026.
• Will not stand for reelection and term ends at the 2026 Annual Meeting (will remain until that meeting concludes).
• Transition Agreement Amendment effective June 3, 2026; amends the November 26, 2024 Transition Agreement.
• Outstanding unvested stock options are eligible to continue vesting during the term of the amendment.

Why It Matters

• This is a planned, orderly board departure (not a disagreement), which reduces immediate governance risk.
• The consulting arrangement provides continuity and access to Prensky’s expertise after he leaves the Board, which may ease transition for management and the Board.
• Continued vesting of his unvested options may affect future share-based compensation expense and potential share overhang; investors should watch proxy and 10-K disclosures for the full agreement terms.